Patents by Inventor Hongjiang Xu

Hongjiang Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12240811
    Abstract: Provided is a compound of formula I or II, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and the medical uses thereof in treating diseases benefiting from the capsid protein assembly inhibitor, particularly diseases caused by hepatitis B virus infection.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: March 4, 2025
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yinsheng Zhang, Wangwei Ao, Yuan Li, Hui Wang, Hangzhou Shen, Jie Ni, Huan Zhang, Jie Wu, Li Zhang, Kai Cao, Peng Lu, Xushi Liu, Jie Wang, Tianxiao Zhao, Xingfeng Ge, Dandan Lu, Shuo Chen, Xueqin Ma, Wei Shi, Xiaojin Wang, Hongjiang Xu
  • Publication number: 20250034165
    Abstract: The present disclosure relates to a compound containing cycloalkyl or haloalkyl, and specifically discloses a compound represented by formula I?, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof in treating tumors.
    Type: Application
    Filed: November 30, 2022
    Publication date: January 30, 2025
    Inventors: Fei LIU, Yan PENG, Hongjiang XU, Taotao FENG, Xiquan ZHANG, Cheng REN, Wei SHI
  • Patent number: 12195468
    Abstract: Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.
    Type: Grant
    Filed: October 12, 2019
    Date of Patent: January 14, 2025
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Hongjiang Xu, Mincheng Zhang, Ying Zhang, Wei Song, Ling Yang, Xiquan Zhang
  • Publication number: 20250002472
    Abstract: A pyridyl-containing compound represented by formula I and a preparation method therefor, and the use thereof in the preparation for a drug for treating tumors.
    Type: Application
    Filed: October 28, 2022
    Publication date: January 2, 2025
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Fei LIU, Hongjiang XU, Yan PENG, Wei SHI, Jiawei ZHOU, Jiajia GU
  • Publication number: 20240383994
    Abstract: Provided are an anti-CD40 antibody and a use thereof, such as a mouse, human, chimeric, or humanized antibody specifically binding to CD40, and an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, and an expression vector and a host cell for expressing the antibody or the antigen-binding fragment thereof. Further provided are a preparation method and a use method for the antibody or the antigen-binding fragment thereof, comprising treating and preventing immune diseases.
    Type: Application
    Filed: September 23, 2022
    Publication date: November 21, 2024
    Inventors: Zhenzhen LU, Yujie WANG, Zhengping ZHANG, Hongjiang XU, Wei ZHAO
  • Patent number: 12128047
    Abstract: The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: October 29, 2024
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xiquan Zhang, Ling Yang, Ying Zhang, Mincheng Zhang, Wei Song, Hongjiang Xu
  • Patent number: 12129603
    Abstract: A ground rail transfer device includes: a support rail provided on the ground and used for unloading a vertical load of a bogie in a rail vehicle; a guide rail provided on the ground and used for driving the bogie to perform a rail transfer operation; and a transition plate provided on the ground and located between a first rail and a second rail which are different in a gauge; wherein a difference between the top surface height of the transition plate and the top surface height of the first rail is equal to a distance between a wheel rim vertex circle and a wheel tread of the rail vehicle.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 29, 2024
    Assignee: CRRC TANGSHAN CO., LTD.
    Inventors: Xiaojun Zhang, Jianke Zheng, Lijun Zhang, Hongjiang Xu, Xiuyu Sun, Feng Zhao, Yongjiang Ma, Xueyi Song, Guangsheng Zheng, Taoguang Hao, Wei Wang
  • Patent number: 12116356
    Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: October 15, 2024
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yinsheng Zhang, Wangwei Ao, Yuan Li, Hui Wang, Hangzhou Shen, Jie Ni, Huan Zhang, Jie Wu, Li Zhang, Kai Cao, Peng Lu, Xushi Liu, Jie Wang, Tianxiao Zhao, Xingfeng Ge, Dandan Lu, Shuo Chen, Xueqin Ma, Wei Shi, Xiaojin Wang, Hongjiang Xu
  • Publication number: 20240294635
    Abstract: Provided are an antigen-binding polypeptide binding to CD47 or an antigen-binding portion thereof, nucleic acids encoding the polypeptide, vector, cell or pharmaceutical composition. The polypeptide can reduce a tumor or inhibit the growth of tumor cells, treat cancer, promote macrophage phagocytosis, and the like.
    Type: Application
    Filed: April 1, 2021
    Publication date: September 5, 2024
    Inventors: Qiu Gui, Hong Zhu, Liangliang Wang, Xiaoyun Zhang, Xiaofang Zou, Hengqiao Shen, Hongjiang Xu, Ling Yang
  • Publication number: 20240270857
    Abstract: An anti-IL-36R antibody and a use thereof, in particular, a mouse, chimeric or humanized antibody or an antigen-binding fragment thereof binding to IL-36R; a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, as well as an expression vector and host cell used to express the antibody or the antigen-binding fragment thereof. In addition, a preparation method and a use of the antibody or the antigen-binding fragment thereof, including treatment and prevention of IL-36/IL-36R-mediated diseases and disorders.
    Type: Application
    Filed: June 17, 2022
    Publication date: August 15, 2024
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xi LONG, Hongjiang XU, Wei SHI, Liangliang WANG, Zhenzhen LU
  • Patent number: 12030880
    Abstract: The present invention relates to a iminosulfanone compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: July 9, 2024
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shouyao Holdings (Beijing) Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd.
    Inventors: Jijun Li, Yan Zhu, Yeliu Wang, Xianxing Shang, Huting Wang, Weinan He, Qin Yan, Yinghui Sun, Kai Zhang, Chang Lu, Hongjiang Xu, Xin Tian, Ling Yang
  • Publication number: 20240182446
    Abstract: A TYK2 inhibitor compound containing a bicyclic ring and the use thereof in the preparation of a drug for treating or preventing TYK2-related diseases.
    Type: Application
    Filed: January 30, 2022
    Publication date: June 6, 2024
    Inventors: Fei Liu, Yanlong Liu, Bin Wang, Hongjiang Xu, Xujing Tang
  • Patent number: 11891405
    Abstract: The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: February 6, 2024
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yinsheng Zhang, Hongjiang Xu, Jing Ren, Qinglin Wang, Zheyang Wu, Chao Jin, Wei Shi, Xiaojin Wang, Xiangyi He, Xiayun Chang, Jie Wang, Tianxiao Zhao
  • Publication number: 20230365700
    Abstract: Provided is an isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human CD40. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. An immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same are further provided.
    Type: Application
    Filed: March 30, 2021
    Publication date: November 16, 2023
    Inventors: Mark Zhiqing MA, Jinyu LIU, Zhengping ZHANG, Hongjiang XU
  • Patent number: 11773079
    Abstract: The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: October 3, 2023
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co, Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
    Inventors: Ticong Huang, Huifeng Xiao, Rui Zhao, Fei Liu, Wei Wei, Hongjiang Xu, Xiaojin Wang, Jingli Wu
  • Publication number: 20230272086
    Abstract: Provided is an ST2 antigen binding protein, such as a mouse, human, chimeric or humanized antibody or antigen binding fragment thereof that specifically binds to ST2. Also provided are nucleic acid molecules encoding the above-mentioned antibodies and antigen binding fragments thereof, and an expression vector and host cell for expressing the antibodies or antigen binding fragments thereof. Further provided are methods for preparing and using the antibodies and antigen binding fragments thereof. The methods comprise treating and preventing IL33/ST2-mediated related diseases or conditions.
    Type: Application
    Filed: May 11, 2021
    Publication date: August 31, 2023
    Inventors: Zhengping Zhang, Shusong Ying, Hongjiang Xu, Ling Yang, Xiquan Zhang, Jun Guo, Wei Shi, Wei Song, Yunyan Zhou
  • Publication number: 20230183208
    Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.
    Type: Application
    Filed: February 6, 2023
    Publication date: June 15, 2023
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yinsheng Zhang, Wangwei Ao, Yuan Li, Hui Wang, Hangzhou Shen, Jie Ni, Huan Zhang, Jie Wu, Li Zhang, Kai Cao, Peng Lu, Xushi Liu, Jie Wang, Tianxiao Zhao, Xingfeng Ge, Dandan Lu, Shuo Chen, Xueqin Ma, Wei Shi, Xiaojin Wang, Hongjiang Xu
  • Publication number: 20230105029
    Abstract: An isolated monoclonal antibody that specifically binds human IL4R?, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. The present disclosure further provides a bispecific molecule, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an Anti-IL4R? antibody or the antigen-binding portion thereof of the disclosure.
    Type: Application
    Filed: February 25, 2021
    Publication date: April 6, 2023
    Inventors: Mingjiu Chen, Wei Tan, Cathy Xiaoyan Zhong, Mark Zhiqing Ma, Shukai Xia, Zhengping Zhang, Hongjiang Xu, Zhijian Lu
  • Publication number: 20230079843
    Abstract: A quinoline derivative for treating rheumatoid arthritis and a use thereof in preparing a pharmaceutical composition for treating rheumatoid arthritis. In particular, a use of the quinoline derivative 1-[[[4-(4-Fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropanamine in treating rheumatoid arthritis.
    Type: Application
    Filed: January 19, 2021
    Publication date: March 16, 2023
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xiquan ZHANG, Ling YANG, Hongjiang XU, Wei SONG, Xiaofang ZOU, Xianju WANG
  • Patent number: 11597716
    Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 7, 2023
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yinsheng Zhang, Wangwei Ao, Yuan Li, Hui Wang, Hangzhou Shen, Jie Ni, Huan Zhang, Jie Wu, Li Zhang, Kai Cao, Peng Lu, Xushi Liu, Jie Wang, Tianxiao Zhao, Xingfeng Ge, Dandan Lu, Shuo Chen, Xueqin Ma, Wei Shi, Xiaojin Wang, Hongjiang Xu